Trial Profile
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary)
- Indications Cytokine release syndrome; Graft-versus-host disease
- Focus Therapeutic Use
- 11 Mar 2024 Planned End Date changed from 13 Sep 2024 to 5 Sep 2024.
- 11 Mar 2024 Planned primary completion date changed from 22 Jun 2024 to 17 Jun 2024.
- 11 Mar 2024 Status changed from recruiting to active, no longer recruiting.